Safety and Effectiveness of Adalimumab in Patients With Rheumatoid Arthritis Over 5 Years of Therapy in a Phase 3b and Subsequent Postmarketing Observational Study

Arthritis Research and Therapy - United Kingdom
doi 10.1186/ar4452
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients With Rheumatoid Arthritis in Japan

Journal of Rheumatology
RheumatologyAllergyImmunology
2013English

Effectiveness, Safety, and Methotrexate Dose-Tapering Pattern Over Two Years of Treatment With Adalimumab and ≥12 Mg/Week Methotrexate for Early Rheumatoid Arthritis: Results of the HAWK Postmarketing Surveillance Study in Japan

Modern Rheumatology
MedicineRheumatology
2019English

Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients

Modern Rheumatology
MedicineRheumatology
2017English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017English

Progression of Subclinical Atherosclerosis Over 5 Years in Patients With Early Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2012English

Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Effectiveness and Safety of Adalimumab in Patients With Ankylosing Spondylitis or Psoriatic Arthritis and History of Anti-Tumor Necrosis Factor Therapy

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2010English

Safety Profile of Baricitinib in Patients With Active Rheumatoid Arthritis With Over 2 Years Median Time in Treatment

Journal of Rheumatology
RheumatologyAllergyImmunology
2019English

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology
MedicineRheumatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy